Cagrilintide and CagriSema: Characterizing Amylin and Co-Formulated Metabolic Standards
Amylin sits outside the incretin axis, which is exactly why it is studied alongside GLP-1. How Cagrilintide is characterized as a reference standard, why CagriSema is best sourced as two separate lots rather than a pre-mixed blend, and the per-component analytical discipline a co-formulation study needs.
Published June 4, 2026 · 7 min read · By Lyochem Regulatory Team
Most of the metabolic reference-standard conversation is about the incretin axis — GLP-1, GIP, glucagon. Cagrilintide sits deliberately outside it: it is a long-acting amylin analog, and amylin acts through a different pathway entirely. That separation is the whole reason Cagrilintide is studied in combination with a GLP-1 agonist rather than as a substitute for one, and it shapes how the combination — referenced in the literature as CagriSema — should be sourced and characterized.
What is Cagrilintide and how is CagriSema characterized as a research standard?
Cagrilintide (CAS 1415456-99-3) is a long-acting amylin analog — described in the literature as an amylin and calcitonin-receptor agonist — studied alongside Semaglutide. CagriSema is the co-formulation of Cagrilintide plus Semaglutide. For research, the two components are best sourced and characterized as separate reference-standard lots, each verified by RP-HPLC purity plus ESI-MS identity against its own theoretical mass, then combined in-protocol. A pre-mixed blend obscures the per-component analytical data a citable methods section needs.
Identity reference
| Component | CAS | Class | Receptor target |
|---|---|---|---|
| Cagrilintide | 1415456-99-3 | Long-acting amylin analog | Amylin / calcitonin receptor |
| Semaglutide | 910463-68-2 | GLP-1 analog (mono-agonist) | GLP-1 receptor |
| CagriSema | (blend; component CAS as above) | Co-formulation | Amylin + GLP-1 (two pathways) |
Cagrilintide is investigational; its precise formula and salt mass are best read from the lot COA for the specific batch rather than a single catalog value. Every Lyochem lot confirms identity by ESI-MS against the theoretical mass for the supplied form and reproduces the value on the batch COA so it can be cited directly in a methods section.
Why amylin is studied with GLP-1, not instead of it
Amylin and GLP-1 act through distinct pathways. In the published metabolic-development literature, GLP-1 agonism and amylin agonism are described as suppressing appetite through different circuits — GLP-1 via hypothalamic pathways and amylin via the area postrema in the brainstem — which is the mechanistic rationale for combining them. Cagrilintide is also described in the literature as engaging the calcitonin receptor in addition to the amylin receptor, placing it firmly outside the incretin axis the GLP-1/GIP/glucagon series occupies.
For a research lab, this context explains the experimental design — why a metabolic study pairs an amylin analog with a GLP-1 agonist to probe two complementary circuits. It is not a claim about the reagent, and Lyochem makes no therapeutic representation about Cagrilintide, Semaglutide, or the combination.
Why a co-formulation should be sourced as two lots
The methodologically clean way to study CagriSema is to source Cagrilintide and Semaglutide as separate characterized lots and prepare the combination in the protocol. The reasons are analytical, not logistical:
- Per-component identity and purity. Cagrilintide and Semaglutide have different masses, different receptors, and different impurity profiles. Confirming each separately by HPLC + MS gives the methods section a per-component evidence trail. A pre-mixed blend collapses two analytical stories into one and makes it harder to attribute an impurity or a purity shortfall to the right component.
- Independent verification before combination. Each standard can be qualified against its own analytical packet — and, for first-lot work, its own sequence-level evidence — before any combination is prepared. That ordering is what a careful study documents.
- Flexibility in ratio. Sourcing separately lets the protocol set and vary the component ratio rather than inheriting a fixed blend ratio, which matters for a research design probing the combination.
Characterizing the amylin component specifically
Cagrilintide's verification follows the same logic as the rest of the long metabolic peptides: RP-HPLC purity at 214 nm, ESI-MS identity against the theoretical mass for the supplied form, water content by Karl Fischer, and counter-ion (acetate by default; TFA suppresses some cell-based readouts). Because Cagrilintide is investigational and relatively long, add LC-MS/MS sequence confirmation for first-lot supplier qualification. For in vivo metabolic-model work, request bacterial endotoxin (LAL) on the specific lot. Read the precise formula and salt mass from the batch COA before a quantitative dosing calculation.
Sourcing scale and framing
Lyochem supplies Cagrilintide and Semaglutide as reference-grade research standards at milligram scale, characterized lot-by-lot, and labelled strictly Research Use Only. For the CagriSema combination, Lyochem supplies the two components as separate characterized lots rather than a pre-mixed blend, so each can be confirmed against its own analytical packet before the combination is prepared in-protocol. Cagrilintide is an investigational compound in the clinical-development program; the material supplied here is a research reagent, not a finished dosage form, and buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
Talk to our regulatory team
Sourcing an amylin standard or the CagriSema component pair?
Send the molecule(s), target purity, intended assay, and whether this is first-lot qualification. Lyochem will map the per-component analytical packet before quote.
Frequently asked questions
- What is Cagrilintide and what receptor does it target?
- Cagrilintide (CAS 1415456-99-3) is a long-acting amylin analog, described in the literature as an amylin and calcitonin-receptor agonist. It sits outside the incretin axis (GLP-1/GIP/glucagon), which is why it is studied in combination with a GLP-1 agonist such as Semaglutide rather than as a substitute for one. It is investigational, so its precise formula and salt mass are best read from the batch COA for the specific lot.
- Why should CagriSema be sourced as two separate lots instead of a pre-mixed blend?
- Cagrilintide and Semaglutide have different masses, receptors, and impurity profiles, so confirming each separately by HPLC + MS gives the methods section a per-component evidence trail. A pre-mixed blend collapses two analytical stories into one and makes it harder to attribute an impurity or purity shortfall to the right component. Sourcing separately also lets each standard be qualified against its own packet before combination, and lets the protocol set the component ratio.
- How is the amylin component verified for research use?
- By RP-HPLC purity at 214 nm, ESI-MS identity against the theoretical mass for the supplied form, water content by Karl Fischer, and counter-ion (acetate by default). Because Cagrilintide is investigational and relatively long, add LC-MS/MS sequence confirmation for first-lot supplier qualification, and request bacterial endotoxin (LAL) for in vivo metabolic-model work. Read the precise formula and salt mass from the batch COA before a quantitative dosing calculation.
- Is Cagrilintide or CagriSema an approved drug?
- They are investigational in the clinical-development program. Lyochem supplies Cagrilintide and Semaglutide as research reference standards for Research Use Only at milligram scale, characterized lot-by-lot — a research reagent, not a finished dosage form and not labelled for human administration. For the combination, the two components are supplied as separate characterized lots. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.